ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

KIRLOSKAR CUMMINS-Expanded Capacity

EPW Research Foundation CIPLA New Projects CIPLA, which is next only to Glaxo in the domestic pharmaceuticals market in terms of market share, saw a mere 1.5 per cent increase in net profit in 1995-96, despite a 21.4 per cent growth in net sales and a 16.2 per cent rise in value of production. Though operating profit increased by 25 per cent, sharp increases in interest charges (up 41.1 per cent), depreciation provision (up 12 per cent) and tax provision (up 47.8 per cent) restricted the rise in the bottorn line.

To read the full text Login

Get instant access

New 3 Month Subscription
to Digital Archives at

₹826for India

$50for overseas users

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top